This week, we’ll review results of a trial that evaluated first-line anti–PD-L1 therapy vs platinum-based chemotherapy in patients with metastatic lung cancer and high PD-L1 expression. We’ll also discuss findings from a study that evaluated whether patients receiving care for advanced cancer based on the recommendations of a molecular tumor board tended to survive longer or experience more time without disease progression.

Coverage of stories discussed this week on ascopost.com:

First-Line Atezolizumab vs Chemotherapy in PD-L1–Positive Metastatic NSCLC: IMpower110

Cancer Therapy Based on Molecular Tumor Board Recommendations: Improvement in Outcomes?

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we’ll review results of a trial that evaluated first-line anti–PD-L1 therapy vs platinum-based chemotherapy in patients with metastatic lung cancer and high PD-L1 expression. We’ll also discuss findings from a study that evaluated whether patients receiving care for advanced cancer based on the recommendations of a molecular tumor board tended to survive longer or experience more time without disease progression.

This week, we’ll review results of a trial that evaluated first-line anti–PD-L1 therapy vs platinum-based chemotherapy in patients with metastatic lung cancer and high PD-L1 expression. We’ll also discuss findings from a study that evaluated whether patients receiving care for advanced cancer based on the recommendations of a molecular tumor board tended to survive longer or experience more time without disease progression.

Coverage of stories discussed this week on ascopost.com:

First-Line Atezolizumab vs Chemotherapy in PD-L1–Positive Metastatic NSCLC: IMpower110

Cancer Therapy Based on Molecular Tumor Board Recommendations: Improvement in Outcomes?

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

This week, we’ll review results of a trial that evaluated first-line anti–PD-L1 therapy vs platinum-based chemotherapy in patients with metastatic lung cancer and high PD-L1 expression. We’ll also discuss findings from a study that evaluated whether patients receiving care for advanced cancer based on the recommendations of a molecular tumor board tended to survive longer or experience more time without disease progression.

Coverage of stories discussed this week on ascopost.com:

First-Line Atezolizumab vs Chemotherapy in PD-L1–Positive Metastatic NSCLC: IMpower110

Cancer Therapy Based on Molecular Tumor Board Recommendations: Improvement in Outcomes?

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> First-Line Atezolizumab vs Chemotherapy in PD-L1–Positive Metastatic NSCLC: IMpower110

This week, we’ll review results of a trial that evaluated first-line anti–PD-L1 therapy vs platinum-based chemotherapy in patients with metastatic lung cancer and high PD-L1 expression. We’ll also discuss findings from a study that evaluated whether patients receiving care for advanced cancer based on the recommendations of a molecular tumor board tended to survive longer or experience more time without disease progression.

Coverage of stories discussed this week on ascopost.com:

First-Line Atezolizumab vs Chemotherapy in PD-L1–Positive Metastatic NSCLC: IMpower110

Cancer Therapy Based on Molecular Tumor Board Recommendations: Improvement in Outcomes?

To listen to more podcasts from ASCO, visit asco.org/podcasts.

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Cancer Therapy Based on Molecular Tumor Board Recommendations: Improvement in Outcomes?